Ignite Creation Date:
2024-05-05 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00443209
Status:
COMPLETED
Last Update Posted:
2018-10-17
First Post:
2007-02-28
Brief Title:
Telcagepant MK-0974 Long-Term Safety Study in Adult Participants With Acute Migraine MK-0974-012
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Multicenter Double-Blind Active-Controlled Parallel Group Study to Examine the Safety Tolerability and Efficacy of Oral MK-0974 for the Long Term Treatment of Acute Migraine With or Without Aura
Status:
COMPLETED
Status Verified Date:
2018-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the safety and tolerability of telcagepant MK-0974 in the long-term treatment of acute migraine in adult participants The primary hypothesis of this study is that telcagepant is well tolerated in the long-term treatment of acute migraine in adult participants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MK-0974-012 | OTHER | None | None |
| 2006_524 | OTHER | Telerx Study Number | None |